Fenoldopam
Corlopam (fenoldopam) is a small molecule pharmaceutical. Fenoldopam was first approved as Corlopam on 1997-09-23. It is used to treat heart failure, malignant hypertension, and renovascular hypertension in the USA. The pharmaceutical is active against D(1A) dopamine receptor. In addition, it is known to target D(4) dopamine receptor and D(1B) dopamine receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Corlopam (generic drugs available since 2004-10-12)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fenoldopam mesylate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CORLOPAM | Hospira | N-019922 RX | 1997-09-23 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| corlopam | New Drug Application | 2020-10-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| heart failure | EFO_0003144 | D006333 | I50 |
| malignant hypertension | EFO_1001031 | D006974 | — |
| renovascular hypertension | EFO_1001153 | D006978 | I15.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
180 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyslipidemias | D050171 | HP_0003119 | 5 | 8 | 6 | 8 | 5 | 29 | |
| Hypertriglyceridemia | D015228 | EFO_0004211 | 1 | 3 | 5 | 9 | 5 | 23 | |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | 2 | 8 | 3 | 3 | 16 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 2 | 5 | 5 | 3 | 14 |
| Hypercholesterolemia | D006937 | HP_0003124 | 1 | 1 | 5 | 2 | — | 9 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 2 | 2 | 4 | 8 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | 2 | — | 1 | 4 | 7 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | 3 | 3 | 1 | 7 | |
| Insulin resistance | D007333 | EFO_0002614 | — | 1 | — | 1 | 4 | 6 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | 1 | 1 | 1 | 5 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biliary liver cirrhosis | D008105 | K74.3 | 1 | 3 | 2 | — | — | 5 | |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 2 | — | 2 | 4 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | 2 | — | — | 3 | |
| Covid-19 | D000086382 | U07.1 | — | 1 | 1 | — | 1 | 3 | |
| Hyperlipoproteinemia type v | D006954 | Orphanet_70470 | E78.3 | — | — | 1 | — | 1 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | 1 | — | — | 1 |
| Glucose metabolism disorders | D044882 | — | — | 1 | — | — | 1 | ||
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | — | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | 1 | — | — | 1 | |
| Hyperlipoproteinemias | D006951 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 12 | 1 | — | — | 5 | 18 | ||
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 1 | — | — | 1 | 3 |
| Medulloblastoma | D008527 | — | 1 | — | — | — | 1 | ||
| Ependymoma | D004806 | — | 1 | — | — | — | 1 | ||
| Leukemia | D007938 | C95 | — | 1 | — | — | — | 1 | |
| Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
| Sarcoma | D012509 | — | 1 | — | — | — | 1 | ||
| Lymphoma | D008223 | C85.9 | — | 1 | — | — | — | 1 | |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | 1 | |
| Huntington disease | D006816 | G10 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fatty liver | D005234 | — | — | — | — | 2 | 2 | ||
| Inflammation | D007249 | — | — | — | — | 1 | 1 | ||
| Cytokinesis | D048749 | — | — | — | — | 1 | 1 | ||
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
| Neonatal jaundice | D007567 | P59.9 | — | — | — | — | 1 | 1 | |
| Radiodermatitis | D011855 | L58 | — | — | — | — | 1 | 1 | |
| Diabetes complications | D048909 | — | — | — | — | 1 | 1 | ||
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 1 | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 1 | 1 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FENOLDOPAM |
| INN | fenoldopam |
| Description | Fenoldopam is a benzazepine. It has a role as a dopaminergic antagonist, a vasodilator agent, an alpha-adrenergic agonist, a dopamine agonist and an antihypertensive agent. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 67227-56-9 |
| RxCUI | 24853 |
| ChEMBL ID | CHEMBL588 |
| ChEBI ID | 5002 |
| PubChem CID | 3341 |
| DrugBank | DB00800 |
| UNII ID | INU8H2KAWG (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,003 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,044 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more